Skip to Main Content

Roche said Wednesday that an experimental cancer immunotherapy directed against a target called TIGIT failed to slow the progression of a less common but aggressive type of lung cancer.

The negative result is the first from a group of late-stage clinical trials that the Swiss pharma giant is conducting for its anti-TIGIT drug called tiragolumab. The company has invested heavily in the drug because of its potential to greatly expand the pool of patients who might benefit from treatments that work by activating the immune system to find and kill tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!